Articles related to OVARIAN CANCER

This version of the carboplatin AUC calculator includes a standard multi-clearance output to help you make an informed decision in determining an appropriate final carboplatin dose. Added bonus? Be sure to check the link to the “new version,” which includes the CKD-EPI equation (corrected for BSA) as an additional clearance equation.

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.